Search clinical trials for: gastric cancer (including stomach and gastroesophageal junction (GEJ))

Total 474262 results

BioNTech SE

Terminated

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors

Gastric Cancer | Pancreatic Cancer | Solid Tumor | Metastatic Cancer | Cholangiocarcinoma | Esophageal Adenocarcinoma | Biliary Tract Cancer | Gastroesophageal Junction Adenocarcinoma

United States, Canada
Leap Therapeutics, Inc.

Available

Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors

Gastric Cancer | Ovarian Cancer | Gastric Adenocarcinoma | Carcinosarcoma | Endometrial Cancer | Adenocarcinoma of the Gastroesophageal Junction | GastroEsophageal Cancer | Uterine Cancer | Esophageal Neoplasm | Squamous Cell Carcinoma

United States
Fondazione Policlinico Universitario Agostino Gemelli...

Completed

Radiomics-based Models for the Prediction of Pathological Response to Neoadjuvant Therapy in Gastric and Gastroesophageal Cancer (RADI-S)

Patients With Locally Advanced Carcinoma of the Stomach and Oesophagogastric Junction
Federation Francophone de Cancerologie Digestive
Eli Lilly and Company

Active, not recruiting

Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients (SOCRATE)

Stomach Cancer | Gastric Cancer | Gastroesophageal Junction Adenocarcinoma | Stomach Neoplasm

France
Exelixis

Active, not recruiting

Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Renal Cell Carcinoma | Head and Neck Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Castration-resistant Prostate Cancer | Urothelial Carcinoma | Differentiated Thyroid Cancer | Gastroesophageal... and other conditions

United States, Australia, Belgium, France, Germany, Italy, Netherlands, Spain, United Kingdom
Eastern Cooperative Oncology Group
National Cancer Institute (NCI); ECOG-ACRIN Cancer Research Group

Withdrawn

C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer

Gastrointestinal Cancer | Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Adenocarcinoma of the Esophagus | Stage IV Esophageal Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric... and other conditions

United States
University Hospital Heidelberg
German Cancer Research Center; University Hospital Dresden

Active, not recruiting

OPPOSITE: Outcome Prediction Of Systemic Treatment in Esophagogastric Carcinoma (OPPOSITE)

Esophageal Neoplasms | Gastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Gastric Neoplasm

Germany
Vall d'Hebron Institute of Oncology

Active, not recruiting

Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC) (MONEO)

Stomach Neoplasms | Gastroesophageal Junction Adenocarcinoma

Spain
M.D. Anderson Cancer Center

Completed

Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology

Diseases of Oesophagus Stomach and Duodenum

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer

Gastric Adenocarcinoma | Peritoneal Carcinomatosis | Gastroesophageal Junction Adenocarcinoma

United States
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)

Gastric Neoplasms | Gastroesophageal Junction Adenocarcinoma

China, Korea, Republic of, Malaysia, Taiwan
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer

Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Postneoadjuvant... and other conditions

United States
Yonsei University

Completed

Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer

Gastric Cancer | Gastroesophageal Junction Cancer

Korea, Republic of
Fox Chase Cancer Center
National Cancer Institute (NCI)

Completed

Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer

Adenocarcinoma of the Gastroesophageal Junction | Squamous Cell Carcinoma of the Esophagus | Adenocarcinoma of the Esophagus | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer and other conditions

United States
MacroGenics
Merck Sharp & Dohme LLC

Completed

Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

Stomach Cancer | Gastric Cancer | Esophageal Cancer

Korea, Republic of, United States, Taiwan, Singapore, Canada
Silverback Therapeutics

Active, not recruiting

A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

HER2 Positive Solid Tumors

United States, Korea, Republic of, Australia
Daiichi Sankyo Co., Ltd.
AstraZeneca

Completed

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]

Neoplasm, Gastrointestinal

Korea, Republic of, Japan
Genentech, Inc.

Completed

A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

Gastric Cancer

Spain, Korea, Republic of, Italy, United Kingdom, United States, Singapore, Taiwan, Germany, Malaysia, Hong Kong, France
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Enrolling by invitation

Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer

Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer

China
Incyte Corporation

Completed

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Stomach Cancer | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | NSCLC | Mesothelioma | Squamous Cell Carcinoma of the Head and Neck | Non-small Cell Lung Cancer | Gastroesophageal Junction Cancer | Urothelial... and other conditions

United States
Eli Lilly and Company

Completed

A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer (RAINFALL)

Metastatic Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Germany, Italy, Spain, United States, Hungary, Russian Federation, Poland, Belgium, Netherlands, France, Czechia, Mexico, Argentina, Canada, Denmark, Finland, Israel, Japan, Puerto Rico, United Kingdom
Pamela L. Kunz
Genentech, Inc.

Completed

Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma

Stomach Cancer | Gastrointestinal Stromal Tumor (GIST) | Gastric (Stomach) Cancer | Neoplasm of Cardioesophageal Junction

United States
AIO-Studien-gGmbH
Taiho Pharmaceutical Co., Ltd.; Nordic Pharma SAS

Completed

Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer (MATEO)

Esophageal Neoplasms | Gastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Gastric Neoplasm | Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction

Germany
National Cancer Institute (NCI)

Terminated

A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer

Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Squamous Cell Carcinoma of the Esophagus | Adenocarcinoma of the Esophagus | Recurrent Esophageal Cancer | Stage IV Esophageal Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma... and other conditions

United States
National Cancer Institute (NCI)

Completed

Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach

Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer

United States
Cancer Institute and Hospital, Chinese Academy...

Completed

Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

China
Hoffmann-La Roche

Completed

A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer (JACOB)

Gastric Cancer

Austria, Belgium, Brazil, Canada, China, Croatia, Finland, Hungary, Italy, Korea, Republic of, Mexico, Poland, Spain, Turkey, United States, Kazakhstan, Peru, Russian Federation, Switzerland, Taiwan, Thailand, Germany, Japan, Malaysia, ... and more
Novartis Pharmaceuticals

Completed

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Metastatic Colorectal Cancer | Gastric Cancer | Advanced Solid Tumors | Metastatic Breast Cancer | Gastroesophageal Junction Cancer | Recurrent Glioblastoma Multiforme | Advanced Pancreatic Adenocarcinoma | Safety | Triple Negative Metastatic Breast Cancer | Dose Escalation | Preliminary Efficacy | Hormone Receptor...

Canada, United Kingdom, Spain, Germany, Italy, Belgium, Australia, United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Gastric Cancer Third Line

Spain, Italy, Australia, Korea, Republic of, Belgium, France, Poland, United States, Czechia, Germany
Eli Lilly and Company

Completed

A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Italy, United States, Spain, Ukraine, Germany, Greece, Czechia, Turkey, Belgium, Sweden, Canada
Bristol-Myers Squibb

Withdrawn

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Stomach Cancer | Gastric Cancer | Cancer of the Stomach | Gastroesophageal Junction

Brazil, Italy, United States, Argentina, Chile, Germany, Spain, Australia, Canada, Portugal, Mexico, Romania, Colombia, Puerto Rico
Sichuan University

Unknown

Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction (CTSCAPOXSEA)

Metastatic Gastric Cancer | Gastroesophageal Junction Adenocarcinoma | Stomach Adenocarcinoma | Locally Advanced Unresectable Gastric Adenocarcinoma

China
Memorial Sloan Kettering Cancer Center

Terminated

Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer

Gastric Cancer | Gastroesophageal Junction Cancer

United States
Memorial Sloan Kettering Cancer Center
Sanofi; University of Pittsburgh; Medical College of Wisconsin; Weill Medical College... and other collaborators

Completed

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer

Gastric Cancer | Esophageal Cancer | Adenocarcinoma of the Gastroesophageal Junction

United States
Hoffmann-La Roche

Completed

A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction Cancer (TOXAG)

Gastric Cancer | Gastroesophageal Junction Cancer

Turkey
Eli Lilly and Company

Completed

A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer

Gastric Cancer

Japan
Eli Lilly and Company

Completed

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

Adenocarcinoma | Gastric Cancer

United States, Canada, Brazil, Czechia, Egypt, Korea, Republic of, Lebanon, Poland, Russian Federation, Spain, Romania, United Kingdom, Australia, Croatia, Italy, Philippines, Thailand, Argentina, Bosnia and Herzegovina, Chile, ... and more
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Terminated

FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer

Gastric Cancer | Gastric Adenocarcinoma | Adenocarcinoma of the Gastroesophageal Junction

United States
Hellenic Cooperative Oncology Group
Boehringer Ingelheim

Completed

Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer (A-GAPP)

Gastric Cancer | Gastroesophageal Junction Cancer

Greece
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach

Gastric Cancer | Esophageal Cancer

United States
Aduro Biotech, Inc.
Merck Sharp & Dohme LLC

Terminated

Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers

Gastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer

Gastric Cancer | Esophageal Cancer

United States
Northwestern University
National Cancer Institute (NCI)

Completed

Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor

Gastric Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
University of California, Irvine
Sanofi-Synthelabo

Terminated

Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma

Gastric Carcinoma | Gastroesophageal Junction Carcinoma

United States
Sun Yat-sen University
Taiho Pharmaceutical Co., Ltd.

Completed

S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients

Gastric Cancer

China
National Cancer Institute (NCI)

Completed

Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer

Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Stage III Gastric Cancer | Adenocarcinoma of the Stomach | Stage IV Esophageal Cancer | Stage III Esophageal Cancer

Canada, United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Adenocarcinoma of the Gastroesophageal Junction | Stage II Gastric Cancer | Stage III Gastric Cancer | Squamous Cell Carcinoma of the Esophagus | Adenocarcinoma of the Stomach | Adenocarcinoma of the Esophagus | Stage III Esophageal Cancer | Stage II Esophageal Cancer

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Gastric Cancer | Esophageal Cancer | Adenocarcinoma of the Gastroesophageal Junction

United States
Kuhnil Pharmaceutical Co., Ltd.
Daiichi Sankyo Co., Ltd.

Terminated

Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer

Gastric Cancer | Gastroesophageal Junction Cancer

Taiwan, Japan, Korea, Republic of

Search clinical trials for: gastric cancer (including stomach and gastroesophageal junction (GEJ))

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations